We are monitoring the impact of COVID-19 on Asia Pacific Urinary Tract Infections Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 4392
Share on
Share on

APAC Urinary Tract Infections Market Research Report – Segmented By Type Of Medication, Type Of Indication and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends and Growth Forecast (2020 to 2025)

Pulished: February, 2020
ID: 4392
Pages: 145

APAC Urinary Tract Infections Market Size (2020 to 2025)

The size of the Urinary Tract Infections Market in the Asia Pacific was worth USD 4.03 billion in 2020 and estimated to be growing at a CAGR of 2.46%, to reach USD 4.55 billion by 2025.

Urinary Tract Infection is an infection which affects parts of the urinary tract. When it affects the lower urinary tract it is called as a bladder infection or cystitis and when it affects the upper urinary tract it is called kidney infection or pyelonephritis. Symptoms from a lower urinary tract include frequent urination, pain with urination, and feeling the need to urinate in spite of having an empty bladder. Symptoms of a kidney infection include flank pain and fever usually in addition to the symptoms of a lower urinary tract infection. The urine may appear bloody in rare cases. In the very young and the very old, symptoms may be non-specific or vague.

The most common cause of infection is E coli, though other fungi or bacteria may rarely might be the cause. Risk factors include female anatomy, diabetes, obesity, sexual intercourse, and family history. Although sexual intercourse is a risk factor, urinary tract infections are not categorized as sexually transmitted infections. If kidney infection occurs, it usually follows a bladder infection but can also result from infection which is blood-borne in nature. Diagnosis in young healthy women can be based alone on symptoms. In those with vague symptoms, diagnosis is difficult since bacteria may be present without infection being present. In complicated cases or when conventional treatments fail, a urine culture may be useful.

The driving factors of Asia Pacific urinary tract infections market are sudden rise in the prevalence rate and the diagnosis for the disease. This has started the opportunities for major players to allocate their resources towards research and development of a combination therapy. This will surely result in the growth of market size during the forecast period. With the launch of new drugs for multiple indications under urinary tract infections, and label expansion for drugs which are already existing, the market is expected to boost further. The generic, low cost competition for some of the drugs is fierce and is forecasted to get more competitive and thus can contribute to offsetting of the figures for current market size.

This research report on the APAC Urinary Tract Infections Market has been segmented and sub-segmented into the following categories:

By Type of Medication:

  • Penicillin & Combinations 
    • Amoxicillin
    • Amoxicillin-Clavulanate Potassium combination
  • Quinolones             
    • Ciprofloxacin
    • Levofloxacin
    • Norfloxacin
    • Nalidixic Acid
  • Aminoglycoside-Antibodies             
    • Gentamicin
    • Amikacin
  • Cephalosporin       
    • Ceftriaxone
    • Cefixime
    • Cefuroxime
    • Cephalexin
  • Sulphonamides     
    • Sulfamethoxazole
    • Trimethoprim combination
  • Azoles & Amphotericin B  
  • Tetracycline            
    • Doxycycline
    • Nitrofurans
  • Nitrofurans 

By Type of Indication:

  • Uncomplicated UTI
  • Complicated UTI   
  • Recurring Complicated UTI               
  • Neurogenic Bladder Infection 

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, Asia Pacific has the largest market in the world for urinary tract infections by share, and is also the fastest growing region. Factors such as increasing geriatric population and growing disposable incomes are expected to propel the market growth in the region.

Noteworthy companies dominating the Asia Pacific Urinary Tract Infections market profiled in this report are Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd., among others.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Type of Medication                 

                                5.1.1 Penicillin & Combinations 

                                                5.1.1.1 Amoxicillin

                                                5.1.1.2 Amoxicillin-Clavulanate Potassium combination

                                5.1.2 Quinolones             

                                                5.1.2.1 Ciprofloxacin

                                                5.1.2.2 Levofloxacin

                                                5.1.2.3 Norfloxacin

                                                5.1.2.4 Nalidixic Acid

                                5.1.3 Aminoglycoside-Antibodies             

                                                5.1.3.1 Gentamicin

                                                5.1.3.2 Amikacin

                                5.1.4 Cephalosporin       

                                                5.1.4.1 Ceftriaxone

                                                5.1.4.2 Cefixime

                                                5.1.4.3 Cefuroxime

                                                5.1.4.4 Cephalexin

                                5.1.5 Sulphonamides     

                                                5.1.5.1 Sulfamethoxazole

                                                5.1.5.2 Trimethoprim combination

                                5.1.6 Azoles & Amphotericin B  

                                5.1.7 Tetracycline            

                                                5.1.7.1 Doxycycline

                                                5.1.7.2 Nitrofurans

                                5.1.8 Nitrofurans             

                                5.1.9  Y-o-Y Growth Analysis, By Type of Medication       

                                5.1.10  Market Attractiveness Analysis, By Type of Medication   

                                5.1.11  Market Share Analysis, By Type of Medication    

                5.2 Type of Indication                    

                                5.2.1 Uncomplicated UTI              

                                5.2.2 Complicated UTI   

                                5.2.3 Recurring Complicated UTI               

                                5.2.4 Neurogenic Bladder Infection         

                                5.2.5 Y-o-Y Growth Analysis, By Type of Indication           

                                5.2.6 Market Attractiveness Analysis, By Type of Indication         

                                5.2.7 Market Share Analysis, By Type of Indication           

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Type of Medication

                                                6.1.3.2 By Type of Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Type of Medication

                                                6.1.4.2 By Type of Indication

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Type of Medication

                                                6.1.5.2 By Type of Indication

                6.2 China                             

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea                               

                6.6 Australia                      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Pfizer, Inc.                   

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 AstraZeneca plc                        

                8.3 Johnson & Johnson                 

                8.4 Novartis International AG.                   

                8.5 F. Hoffmann La Roche Ltd.                   

                8.6 Teva Pharmaceutical Industries Ltd.                

                8.7 Boehringer Ingelheim GmbH                              

                8.8 Cipla Ltd.                      

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms by type, packaging and meat type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the North america market; which includes broadly demographic, economic and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia Pacific Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  2. Asia Pacific Penicillin & Combinations Market, By Region, From 2020 to 2025 (USD Million)
  3. Asia Pacific Quinolones Market, By Region, From 2020 to 2025 (USD Million)
  4. Asia Pacific Aminoglycoside-Antibodies Market, By Region, From 2020 to 2025 (USD Million)
  5. Asia Pacific Cephalosporin Market, By Region, From 2020 to 2025 (USD Million)
  6. Asia Pacific Sulphonamides Market, By Region, From 2020 to 2025 (USD Million)
  7. Asia Pacific Azoles & Amphotericin B Market, By Region, From 2020 to 2025 (USD Million)
  8. Asia Pacific Tetracycline Market, By Region, From 2020 to 2025 (USD Million)
  9. Asia Pacific Nitrofurans Market, By Region, From 2020 to 2025 (USD Million)
  10. Asia Pacific Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  11. Asia Pacific Uncomplicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  12. Asia Pacific Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  13. Asia Pacific Recurring Complicated UTI Market, By Region, From 2020 to 2025 (USD Million)
  14. Asia Pacific Neurogenic Bladder Infection Market, By Region, From 2020 to 2025 (USD Million)
  15. Japan Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  16. Japan Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  17. China Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  18. China Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  19. India Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  20. India Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  21. Australia Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  22. Australia Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)
  23. South Korea Urinary Tract Infections Market, By Type of Medication, From 2020 to 2025 (USD Million)
  24. South Korea Urinary Tract Infections Market, By Type of Indication, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample